PURPOSE: Glaucoma is a group of neurodegenerative eye diseases that lead to progressive vision loss. Management of glaucoma focuses on decreasing intraocular pressure (IOP) with the most common treatment consisting of topical ocular hypotensive medications. Latanoprostene Bunod 0.024% (LBN) is a topical ocular hypotensive prostaglandin (PGA) indicated for the reduction of IOP in open-angle glaucoma (OAG) or ocular hypertension (OHT). The study quantifies changes in intraocular pressure in patients after switching to LBN from prior pharmacotherapy

METHODS: Adult patients (=18 years) with a diagnosis of OAG/OHT and =1 LBN prescription were identified in the American Academy of Ophthalmology IRIS© Registry (Intelligent Research in Sight) linked to Komodo HealthMap claims. Study period was from July 2017 - June 2023. Index date was the date of first prescription of LBN. The IOP at baseline and after treatment switch to LBN was compared at two follow-up visits, (1) at any time between day 30 and day 180 post-LBN claim, (2) in a subset of patients at any time between day 90 and day 180 post-LBN. Statistical significance was set at p<0.05>

RESULTS: 833 patients with OAG/OHT met the study selection criteria that switched to LBN from prior pharmacotherapy. The mean (SD) reduction in IOP at first follow-up was 2.8 (4.7) mmHg after switching to LBN. A vast majority (55.3%) of patients switched from PGA monotherapy to LBN monotherapy with a mean (SD) IOP reduction of 2.4 (3.7) mmHg and 15.5% patients switched from non-PGA combination to LBN with a mean (SD) IOP reduction of 3.3 (6.1) mmHg. Of the 833 patients, 137 patients were followed up for a second IOP measurement with a mean (SD) reduction in IOP of 3.6 (5.2) mmHg compared to baseline. Of these patients, 53.2% switched from PGA monotherapy to LBN with a mean (SD) IOP reduction of 3.1 (4.2) mmHg. IOP reductions were statistically significant

CONCLUSIONS: Switching treatment from current mono- or combination pharmacotherapy to LBN in patients with OAG/OHT shows greater than 2-mmHg reduction in IOP in majority of the patients supporting the effectiveness of LBN. Reducing IOP, a modifiable risk factor can reduce the risk of visual field loss. These large-scale real-world study findings are consistent with those observed in smaller observational studies and clinical trials, confirming LBN effectiveness in real-world clinical practice